Sutter Health’s CPMC Physician Leader Honored with Humanitarian Award
Kevin Kim, M.D., a physician with Sutter Pacific Medical Foundation and director of clinical research for the Center for Melanoma Research and Treatment at Sutter Health’s California Pacific Medical Center (CPMC), will be honored with a Humanitarian Award from the Melanoma Research Foundation.
“Through his steadfast commitment to research and to his clinical practice, Dr. Kim embodies the dedication that this award represents,” said CPMC CEO Warren Browner, M.D., MPH. “Patients across California and beyond have benefited from his skills and accomplishments as a physician and scientist.”
Dr. Kim leads CPMC’s efforts to build a database and tumor bank of tissue samples from patients with melanoma. He and colleagues, including Mohammed Kashani-Sabet, M.D., will use these samples to create new diagnostic tests and personalized therapies for all stages of the disease.
“This is an incredibly exciting time in melanoma research,” says Dr. Kim. “With the advancement of these treatments and our expanding knowledge of tumor genetic biomarkers and cancer immunology, we can focus our efforts on bringing novel, more personalized therapies to patients at CPMC. I am thrilled to receive this great honor from the Melanoma Research Foundation.”
Dr. Kim’s research was critical to early drug development of vemurafenib and dabrafenib (both BRAF inhibitors) and trametinib (a MEK inhibitor)—FDA-approved drugs that have greatly advanced the treatment of patients with BRAF-mutant metastatic melanoma.
Dr. Kim will receive his award tomorrow at the Wings of Hope for Melanoma Gala in San Francisco, an annual event that celebrates leaders in the melanoma medical community and recognizes individuals who are battling melanoma.
Before joining CPMC in 2014, Dr. Kim served as a physician and professor at the University of Texas MD Anderson Cancer Center. He is a prominent medical oncologist, board-certified in internal medicine and medical oncology. He leads clinical trials investigating the biology of genetic mutations in melanoma, and new combinations of targeted and immunotherapies. He earned his medical degree from the University of Illinois and completed residency training at the Mayo Clinic in Rochester. He completed his fellowship in medical oncology/hematology at the University of Texas MD Anderson Cancer Center.